Altimmune announces first dosing of all subjects in phase 2 momentum trial of pemvidutide in subjects with obesity or overweight

Twenty-four week interim analysis on approximately 160 subjects planned for q1 2023 twenty-four week interim analysis on approximately 160 subjects planned for q1 2023

ALT Ratings Summary

ALT Quant Ranking